<DOC>
	<DOCNO>NCT00002559</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy consist paclitaxel , cisplatin , ifosfamide treat patient ovarian testicular germ cell tumor refractory platinum-containing chemotherapy .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Germ Cell Tumors That Have Not Responded Previous Cisplatin</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity optimal dose paclitaxel combine cisplatin ifosfamide patient germ cell tumor favorable prognostic feature resistance cisplatin . - Determine efficacy regimen salvage therapy patient . OUTLINE : This dose escalation study paclitaxel . Patients receive paclitaxel IV continuously day 1 cisplatin IV 20 minute ifosfamide IV 30 minute day 2-6 . Filgrastim ( G-CSF ) administer subcutaneously ( SC ) day 7-18 blood count recover . Treatment continue every 3 week 4 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose-limiting toxicity . Additional patient receive paclitaxel MTD . After completion chemotherapy , patient may undergo resection residual mass . PROJECTED ACCRUAL : A total 18-43 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven germ cell tumor resistant platinumbased chemotherapy regimen Active disease meeting 1 follow condition : Measurable evaluable disease Elevated serum tumor marker ( alphafetoprotein human chorionic gonadotropin ) Unresectable residual disease postchemotherapy surgery Favorable prognostic factor achieve complete response ( CR ) cisplatinbased salvage therapy require , include follow : No 1 prior regimen 6 prior course cisplatin Testis ovarian germ cell primary site Prior CR cisplatin therapy Incomplete response firstline therapy base either carboplatin suboptimal regimen cisplatin PATIENT CHARACTERISTICS : Age : 15 Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8.0 g/dL Hepatic : Not specify Renal : Creatinine clearance great 50 mL/min Renal dysfunction due ureteral obstruction tumor allow discretion principal investigator Cardiovascular : If history significant cardiac disease , evaluation clearance cardiologist require prior entry Other : No active infection well control antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior paclitaxel ifosfamide At least 3 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Recovered recent surgery</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
</DOC>